Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have earned a consensus rating of “Buy” from the thirteen analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $107.00.

MNPR has been the topic of a number of research analyst reports. BTIG Research reiterated a “buy” rating and issued a $104.00 target price on shares of Monopar Therapeutics in a research note on Monday. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Barclays set a $125.00 price target on Monopar Therapeutics and gave the company an “overweight” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st.

Insider Buying and Selling at Monopar Therapeutics

In related news, CFO Quan Anh Vu acquired 1,500 shares of the stock in a transaction dated Friday, December 26th. The shares were acquired at an average price of $69.95 per share, for a total transaction of $104,925.00. Following the completion of the purchase, the chief financial officer owned 1,500 shares in the company, valued at approximately $104,925. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new position in shares of Monopar Therapeutics during the third quarter valued at about $18,904,000. Deerfield Management Company L.P. acquired a new stake in Monopar Therapeutics during the third quarter worth about $13,048,000. TCG Crossover Management LLC bought a new position in Monopar Therapeutics during the third quarter valued at about $12,496,000. Vanguard Group Inc. raised its holdings in Monopar Therapeutics by 140.7% in the 3rd quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock valued at $17,005,000 after acquiring an additional 121,729 shares in the last quarter. Finally, Vivo Capital LLC bought a new stake in shares of Monopar Therapeutics in the 3rd quarter worth approximately $7,391,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Stock Performance

MNPR opened at $65.48 on Tuesday. The firm has a market cap of $437.60 million, a P/E ratio of -19.03 and a beta of 1.46. The business has a 50 day moving average price of $71.39 and a 200 day moving average price of $65.92. Monopar Therapeutics has a twelve month low of $26.06 and a twelve month high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.02). As a group, analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.